HP
DNLI icon

HealthInvest Partners’s Denali Therapeutics DNLI Stock Holding History

HealthInvest Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$4.39K Buy
+158
New +$4.7K 0.01% 53

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

HealthInvest Partners's DNLI Position: Q4 2022 in Review

HealthInvest Partners opened a new position in Denali Therapeutics (DNLI) in Q4 2022: 158 shares worth $4.39K. The stake represents 0.01% of the portfolio and ranks #53 among its holdings.

199 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

  • HealthInvest Partners held 158 shares of Denali Therapeutics worth $4.39K as of Q4 2022.
  • Denali Therapeutics was a new HealthInvest Partners position in Q4 2022.
  • Denali Therapeutics made up 0.01% of HealthInvest Partners's portfolio in Q4 2022, its #53 holding.
  • 199 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.